A first-in-man clinical trial was completed with VentriGel, an extracellular matrix hydrogel derived from decellularized porcine myocardium, in post-MI patients.
SUMMARY
This study evaluated the safety and feasibility of transendocardial injections of VentriGel, a cardiac extracellular matrix hydrogel, in early and late post-myocardial infarction (MI) patients with left ventricular (LV) dysfunction.
VentriGel was delivered in 15 patients with moderate LV dysfunction (25% # LV ejection fraction # 45%) who were between 60 days to 3 years post-MI and were revascularized by percutaneous coronary intervention. The primary endpoints were incidence of adverse events and abnormal clinical laboratory results. This first-in-man O ver the past 2 decades, there has been extensive interest in using regenerative medicine to treat patients with myocardial infarction (MI) and ischemic heart failure. Although several growth factor and gene therapeutics have been explored, the vast majority of trials have tested different types of stem cells (1) . However, tissues are not just comprised of cells but also include a scaffolding framework, the extracellular matrix (ECM).
The ECM contains numerous proteins and proteoglycans with a unique tissue-specific composition that provides cues, which influence all aspects of cell behavior necessary for proper tissue function as well as repair (2) . After an MI, there is not only cell death but also an inflammatory response and upregulation of matrix metalloproteinases that degrade the native cardiac ECM (3) . After the initial inflammation, the area is replaced by a collagen-rich scar. With the goal of replacing this abnormal microenvironment with healthy myocardial ECM cues to facilitate cardiac repair, we developed an injectable, catheterdeliverable hydrogel derived from porcine decellularized myocardial ECM (4) . This material can be stored in a lyophilized form and rehydrated with sterile water to form a liquid that gels into a porous and fibrous scaffold upon intramyocardial injection, enabling endogenous cell infiltration and cardiac repair (4, 5) .
In vitro analyses showed the potential of the material to promote recruitment and/or proliferation of vascular cells and stem cells as well as cardiac differentiation of stem cells (4, (6) (7) (8) (9) (10) . In rat MI models, the hydrogel promoted a pro-remodeling instead of a proinflammatory environment, increased neovascularization, and reduced fibrosis. The hydrogel also decreased border zone cardiomyocyte apoptosis, led to a shift in cardiomyocyte metabolism, and increased cardiac muscle leading to improvements in global cardiac function (5, 11) . In a more translatable porcine MI model, the material increased cardiac muscle, reduced fibrosis, and led to significant improvements in both global and regional function after percutaneous, transendocardial delivery (12) . Importantly, preclinical safety studies showed biocompatibility, hemocompatibility, and lack of arrhythmias (5, 12) . This work motivated testing the material, commercially termed VentriGel (Ventrix, Inc., San Diego, California), in post-MI patients.
Accordingly, we developed a first-in-man, singlearm, multicenter trial to evaluate the safety, feasibility, and preliminary efficacy of percutaneous transendocardial delivery of VentriGel in early and late MI patients with left ventricular (LV) dysfunc- 
tion. This injectable biomaterial approach represents

RESULTS
PATIENTS. All patients gave written informed consent; 22 patients were consented and screened, and 15 patients were subsequently enrolled between September 2015 and July 2017 (Supplemental Table 1 ).
The majority of patients were men (n ¼ 12) and had Class II heart failure (n ¼ 11). Age ranged from 45 to 69 years, and other pertinent baseline characteristics are summarized in Table 1 . Concomitant medications are listed in Supplemental Table 2 . VentriGel was deliv- SAFETY. Overall, VentriGel was well tolerated, and there were no deaths or patients who discontinued from the study. No adverse event was reported as definitely related to VentriGel (Supplemental Table 3) or the mapping/injection procedure. One major adverse cardiac event, cardiogenic shock, and 1 moderate event, complete heart block, both in the first patient treated were reported as possibly related for study treatment. This patient's history included trifascicular block, which was added as an exclusion Patients >12 months post-MI at treatment * p = 0.36 p = 0.36 p = 0.17 p = 0.36 p = 0.08 p = 0.08 p = 0.66 p = 0.27 p = 0.95 p = 0.03 p = 0.24 p = 0.22 Table 4 ). Table 6 ). The MLWHFQ score likewise significantly decreased at 1 month (p ¼ 0.045), and a similar decrease was observed at 3 and 6 months but was nonsignificant ( Figure  1C , Supplemental Figure 1C , Supplemental Table 6 ). Improvements in the walk distance ( Patients >12 months post-MI at treatment C p = 0.22 p = 0.17 p = 0.05 p > 0.99 p = 0.89 p = 0.34 p = 0.28 p = 0.85 p = 0.52 p = 0.20 p = 0.05 p = 0.09 acute MI (18, 19) . In phase 2 studies, Algisyl-LVR significantly improved exercise capacity but not measures of LV remodeling (20, 21) , and IK-5001 likewise failed to reduce progressive LV remodeling (22) . Later preclinical studies have shown that passively supporting the infarct wall does not improve long-term cardiac function and suggest that the cell and tissue response to injected biomaterials play a dominant role in cardiac remodeling (23, 24) .
VentriGel is a relatively weak hydrogel, about 2 orders of magnitude lower than the stiffness of healthy myocardium (25) , and therefore would not be ex- Although numerous injectable biomaterials have now been evaluated in preclinical studies in MI and heart failure models, few have actually been delivered via a catheter because this poses unique material design constraints (26, 27) . The quick gelling nature, high viscosity, and/or lack of hemocompatibility prevent the majority of injectable biomaterials from this type of minimally invasive delivery modality.
VentriGel was specifically designed to have the appropriate viscosity and gelation kinetics to facilitate transendocardial delivery, and extensive preclinical safety studies have shown hemocompatibility and a lack of arrhythmias (5, 12) . This study demonstrated the safety and feasibility of transendocardial delivery of VentriGel in post-MI patients with 15 to 18 injections being performed in all patients and without serious adverse events observed to be definitely related to material or mapping/injection procedure.
The first patient, whose pre-treatment history included a trifascicular block, had 2 adverse events variate baseline in these patients as the infarct and peri-infarct regions recover from ischemic injury. In patients, infarct remodeling is typically thought to occur over the first several months, although studies have suggested that the dynamic time period of infarct healing is, in fact, a longer process (28, 29) .
Overall, there were few increases in cardiac medications, and those that did occur were in the early Cardiac Extracellular Matrix Hydrogel for Myocardial Infarction scaffold to enable cell infiltration, and early device trials do not typically include a control group.
Another limitation is that the patients' MIs spanned a relatively large post-infarction time period when the biologic response to VentriGel may vary. Thus, the optimum time to deliver VentriGel remains to be determined and will require a larger trial. However, the beneficial response of patients whose infarcts
were >12 months appears to be an encouraging starting point going forward. Importantly, the study used state-of-the-art MRI imaging rather than echocardiography, which helped reduce variability.
Because injections were limited to wall thickness of >8 mm, we were frequently precluded from injecting into the infarct zone as was performed in the preclinical porcine studies (12) .
CONCLUSIONS
These results support the safety and feasibility of transendocardial injection of VentriGel in post-MI patients with LV dysfunction and introduces a new potential treatment for patients with heart failure.
This trial was novel in many regards including the first injectable biomaterial to be delivered in patients using transendocardial injections, translation of the first proreparative hydrogel for the heart, and translation of the first decellularized ECM hydrogel in any tissue. As such, the significance of this trial reaches beyond the cardiac field because there have been numerous preclinical studies evaluating decellularized ECM hydrogels in various applications in other tissues (36) . Although there is a long precedence of using porcine-derived materials, including decellularized ECM patches (37) , this trial was the first to test an injectable hydrogel form of decellularized ECM in patients and therefore provides important safety and feasibility data and opens up the possibility of using ECM hydrogels in many other applications.
Importantly, this study also provides support for the safety and feasibility of treating post-MI patients with VentriGel and warrants further evaluation in larger randomized clinical trials.
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